Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle

Aquestive's issues are more likely related to manufacturing or packaging rather than efficacy or safety. See why I'm ...
The Manila Times

Independent Proxy Advisory Firms Recommend NuVista Shareholders Vote "For” Proposed Ovintiv Transaction

ISS cites flexibility for NuVista Shareholders to realize certain cash value or continued participation in endorsing the ...
Tax Guru

Section 153C Bar After April 2021: Bulk Assessments Quashed by ITAT

ITAT held that Section 153C cannot be invoked where the satisfaction/hand-over date is after 01.04.2021, quashing multiple assessments framed thereafter. The ruling follows the Madras High Court and ...

QR Codes: A powerful CTA for first-party data

Uniqode reports QR Codes are key for collecting first-party data, offering consent, context, and engagement insights over ...
guardonline.com

Lexaria Releases Annual Letter from the CEO

KELOWNA, BC / / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a ...